Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Helix BioPharma Corp Announces Completion Of Sale Of Rivex Pharma Division To Pharmascience


Friday, 25 Jan 2013 12:59pm EST 

Helix BioPharma Corp announced that the completion of the previously announced sale of its Rivex Pharma division to Pharmascience Inc. (Pharmascience) for gross cash proceeds of $8.5 million, subject to adjustment (the "Rivex Transaction"). The Rivex Transaction was approved by 100% of the votes cast by shareholders present in person or by proxy at Helix's annual general and special meeting held on January 24, 2013. 

Company Quote

2.0
0.0 +0.00%
17 Jul 2014